CU20150020A7 - Composición farmacéutica recubierta que contiene regorafenib - Google Patents

Composición farmacéutica recubierta que contiene regorafenib

Info

Publication number
CU20150020A7
CU20150020A7 CU2015000020A CU20150020A CU20150020A7 CU 20150020 A7 CU20150020 A7 CU 20150020A7 CU 2015000020 A CU2015000020 A CU 2015000020A CU 20150020 A CU20150020 A CU 20150020A CU 20150020 A7 CU20150020 A7 CU 20150020A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
composition containing
containing regorafenib
covered
regorafenib
Prior art date
Application number
CU2015000020A
Other languages
English (en)
Other versions
CU24244B1 (es
Inventor
Dr Susanne Skrabs
Dr Adrian Funke
Dr Mayk Kresse
Dr Ulrich Oberdieck
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20150020(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20150020A7 publication Critical patent/CU20150020A7/es
Publication of CU24244B1 publication Critical patent/CU24244B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención se refiere a una composición farmacéutica recubierta que contiene regorafenib, un hidrato, solvato, metabolito o sal farmacéuticamente aceptable del mismo, o un polimorfo del mismo y su procedimiento de preparación y su uso para tratar trastornos.
CUP2015000020A 2012-09-06 2013-09-05 Composición farmacéutica recubierta que contiene regorafenib CU24244B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12183331 2012-09-06
PCT/US2013/058257 WO2014039677A1 (en) 2012-09-06 2013-09-05 Coated pharmaceutical composition containing regorafenib

Publications (2)

Publication Number Publication Date
CU20150020A7 true CU20150020A7 (es) 2015-05-28
CU24244B1 CU24244B1 (es) 2017-02-02

Family

ID=46963450

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000020A CU24244B1 (es) 2012-09-06 2013-09-05 Composición farmacéutica recubierta que contiene regorafenib

Country Status (43)

Country Link
US (1) US20140065212A1 (es)
EP (2) EP3243508A1 (es)
JP (1) JP6445436B2 (es)
KR (1) KR102162036B1 (es)
CN (5) CN111249247A (es)
AP (1) AP2015008292A0 (es)
AR (1) AR092439A1 (es)
AU (1) AU2013312531B2 (es)
BR (1) BR112015004936B1 (es)
CA (1) CA2883767C (es)
CL (1) CL2015000544A1 (es)
CO (1) CO7310528A2 (es)
CR (1) CR20150114A (es)
CU (1) CU24244B1 (es)
CY (1) CY1118839T1 (es)
DK (1) DK2892507T3 (es)
EA (1) EA027685B1 (es)
ES (1) ES2623205T3 (es)
GT (1) GT201500053A (es)
HK (1) HK1214170A1 (es)
HR (1) HRP20170620T1 (es)
HU (1) HUE032758T2 (es)
IL (1) IL237350B (es)
IN (1) IN2015DN01673A (es)
JO (1) JO3479B1 (es)
LT (1) LT2892507T (es)
MA (1) MA37888B1 (es)
MX (1) MX359922B (es)
MY (1) MY176135A (es)
NZ (1) NZ705578A (es)
PE (1) PE20151005A1 (es)
PH (1) PH12015500460A1 (es)
PL (1) PL2892507T3 (es)
PT (1) PT2892507T (es)
RS (1) RS56019B1 (es)
SA (1) SA515360113B1 (es)
SG (1) SG11201501683WA (es)
SI (1) SI2892507T1 (es)
TW (1) TWI640329B (es)
UA (1) UA115994C2 (es)
UY (1) UY35006A (es)
WO (1) WO2014039677A1 (es)
ZA (1) ZA201501394B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2016531151A (ja) * 2013-09-13 2016-10-06 バイエル ファーマ アクチエンゲゼルシャフト レファメチニブを含有する医薬組成物
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN105496975B (zh) * 2015-12-17 2019-01-04 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
BR112019025478A8 (pt) * 2017-06-02 2022-12-06 Bayer Ag Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer
MX2021000068A (es) * 2018-07-06 2021-03-25 Agios Pharmaceuticals Inc Formas y composiciones farmaceuticas de ivosidenib.
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN113018274A (zh) * 2021-03-10 2021-06-25 药源生物科技（启东）有限公司 一种含羟丙甲纤维素的药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101363679B1 (ko) * 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
CN1265793C (zh) * 2002-11-18 2006-07-26 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2633411A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
US20100316711A1 (en) * 2007-10-25 2010-12-16 Bayer Yakuhin ,Ltd. Nifedipine containing opress coated tablet and method of preparing same
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2012260605B2 (en) * 2011-05-20 2015-02-19 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium

Also Published As

Publication number Publication date
MA37888B1 (fr) 2019-08-30
BR112015004936A2 (pt) 2017-07-04
UA115994C2 (uk) 2018-01-25
PT2892507T (pt) 2017-05-02
EP3243508A1 (en) 2017-11-15
PH12015500460B1 (en) 2015-04-20
SG11201501683WA (en) 2015-04-29
ES2623205T3 (es) 2017-07-10
CN104902878A (zh) 2015-09-09
TWI640329B (zh) 2018-11-11
US20140065212A1 (en) 2014-03-06
TW201414510A (zh) 2014-04-16
AU2013312531A1 (en) 2015-03-12
MA37888A1 (fr) 2018-07-31
CL2015000544A1 (es) 2015-08-21
CU24244B1 (es) 2017-02-02
MY176135A (en) 2020-07-24
DK2892507T3 (en) 2017-05-01
MX359922B (es) 2018-10-16
CN116392598A (zh) 2023-07-07
JP2015527395A (ja) 2015-09-17
CA2883767C (en) 2018-11-13
NZ705578A (en) 2017-10-27
WO2014039677A1 (en) 2014-03-13
LT2892507T (lt) 2017-06-12
RS56019B1 (sr) 2017-09-29
CN111249247A (zh) 2020-06-09
IL237350B (en) 2020-11-30
AP2015008292A0 (en) 2015-02-28
ZA201501394B (en) 2016-07-27
KR20150048872A (ko) 2015-05-07
BR112015004936B1 (pt) 2022-12-06
SA515360113B1 (ar) 2016-08-10
CA2883767A1 (en) 2014-03-13
IN2015DN01673A (es) 2015-07-03
KR102162036B1 (ko) 2020-10-07
EA027685B1 (ru) 2017-08-31
HRP20170620T1 (hr) 2017-06-30
EA201590520A1 (ru) 2015-10-30
UY35006A (es) 2014-03-31
MX2015002815A (es) 2015-05-15
EP2892507B1 (en) 2017-02-01
CO7310528A2 (es) 2015-06-30
PE20151005A1 (es) 2015-06-27
SI2892507T1 (sl) 2017-08-31
PL2892507T3 (pl) 2017-09-29
IL237350A0 (en) 2015-04-30
JP6445436B2 (ja) 2018-12-26
CN116392484A (zh) 2023-07-07
AU2013312531B2 (en) 2017-10-19
CR20150114A (es) 2015-05-11
AR092439A1 (es) 2015-04-22
JO3479B1 (ar) 2020-07-05
CY1118839T1 (el) 2018-01-10
CN116392485A (zh) 2023-07-07
HUE032758T2 (en) 2017-10-30
PH12015500460A1 (en) 2015-04-20
HK1214170A1 (zh) 2016-07-22
GT201500053A (es) 2015-10-12
EP2892507A1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
GT201300249A (es) Aclidinio para uso en la mejora de la calidad del sueño en pacientes respiratorios
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
EA201400444A1 (ru) Производные 2-оксопиперидинила
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
BR112015001169A2 (pt) polimorfo, uso do polimorfo, composição farmacêutica e uso para preparar o polimorfo
CL2015000072A1 (es) Compuestos derivados de azaindol, inhibidores pi3k; metodo de preparacion; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de tratornos inmunologicos, cancer y enfermedades cardiovasculares.